A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC.
Agnese Losurdo(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Giovanna Masci(Humanitas University), Marco Alloisio(IRCCS Humanitas Research Hospital), Monica Zuradelli(Humanitas University), Rita De Sanctis(Humanitas University), Massimo Roncalli(Fondazione Humanitas per la Ricerca), Andrea Sagona(IRCCS Humanitas Research Hospital), Bethania Fernandes(Humanitas University), Elisa Agostinetto(Université Libre de Bruxelles), Alberto Testori(IRCCS Humanitas Research Hospital), Corrado Tinterri(Humanitas University), Valentina Errico(IRCCS Humanitas Research Hospital), Wolfgang Gatzemeier(IRCCS Humanitas Research Hospital), Rosalba Torrisi(IRCCS Humanitas Research Hospital)
Cited by 1
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670